Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus

Süleyman KALELİ, (Sakarya University, Faculty of Medicine, Department of Medical Biology, Sakarya, Turkey)
Ceyhun VARIM, (Sakarya University, Faculty of Medicine, Department of Internal Diseases, Sakarya, Turkey)
Ahmet NALBANT, (Sakarya University, Faculty of Medicine, Department of Internal Diseases, Sakarya, Turkey)
Hayrullah YAZAR, (Sakarya University, Faculty of Medicine, Department of Medical Biochemistry, Sakarya, Turkey)
Mehmet AKDOĞAN (Sakarya University, Faculty of Medicine, Department of Medical Biochemistry, Sakarya, Turkey)
Bezmiâlem Science
12 4
Yıl: 2019 Cilt: 7 Sayı: 1 Sayfa Aralığı: 1 - 7 Metin Dili: İngilizce DOI: 10.14235/bas.galenos.2017.2077 İndeks Tarihi: 24-09-2019

Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus

Öz:
Objective: Diabetic foot ulcers, one of the factors that determine thelife time and quality of life in diabetic patients are one of the mostfrequent causes of hospitalization and surgery. In this study, we aimedto investigate the levels of interleukin (IL)-12 P70, 17, 18, hemoglobin(Hb) A1c, and some parameters in subjects with type 2 diabeticmellitus with diabetic foot and in healthy subjects. Methods: The study was performed on three groups. They werepatients with diabetic foot, with diabetes mellitus type 2 and healthyindividuals (control). IL-12 P70, IL-17, and IL-18, HbA1c levels andother biochemical parameters were compared between three groups.Results: We found higher IL-17, IL-18, white blood cells, glucose andHbA1c in the diabetic group and diabetic foot group than in the controlgroup. IL-12 P70 levels in the diabetic foot group were significantlyhigher than the control group. The performances in diagnosing ofIL-12 P70, 17 and 18 as a biomarker for diabetic foot were foundstatistically significant. IL-12 P70, 17 and 18 levels in diabetic patientswere not different from the levels in patients with diabetic foot.Conclusion: According to our results, IL-12 P70, IL-17 and IL-18 canbe used as biomarkers for diabetic foot. Further studies are needed toshow the role of IL-12 P70, IL-17 and IL-18 levels as a biomarker inchronic inflammatory diseases.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Diyabetik Ayak Sendromu ve Tip 2 Diabetes Mellitusta Enflamasyonun Bir Göstergesi Olarak İnterlökinler

Öz:
Amaç: Diyabet hastalarının yaşam kalitesini ve süresini belirleyen faktörlerden olan diyabetik ayak ülserleri hastanede yatış ve ameliyat nedenlerinden biridir. Bu çalışmada, biz tip 2 diabetes mellituslu hastalarda, diyabetik ayak hastalarında ve sağlıklı bireylerde interlökin (IL)-12 P70, 17, 18, hemoglobin (Hb) A1c ve bazı parametrelerin düzeylerini araştırmayı amaçladık. Yöntemler: Çalışma diyabetik ayak hastaları, tip 2 diabetes mellitus hastaları ve sağlıklı bireylerden (kontrol grubu) oluşmuş üç grup üzerinde gerçekleştirildi. IL-12 P70, IL-17 ve IL-18 düzeyleri, HbA1c düzeyleri ve diğer biyokimyasal testler her üç grupta karşılaştırıldı. Bulgular: Kontrol grubu ile karşılaştırıldığında IL-17, IL-18, beyaz kan hücreleri, glikoz ve HbA1c düzeyleri diabetes mellitus ve diyabetik ayak gruplarında daha yüksek bulundu. Diyabetik ayak grubunda IL-12 P70 seviyeleri kontrol grubuna göre anlamlı olarak yüksek bulundu. Diyabetik ayak teşhisinde bir belirteç olarak IL-12 P70, 17 ve 18 performansları istatistiksel olarak anlamlı bulundu. Diyabetik ayaktaki IL-12 P70, 17 ve 18 düzeyleri tip 2 diyabetli hastalarla karşılaştırıldığında istatistiksel açıdan iki grup arasında anlamlı bir fark bulunmamıştır. Sonuç: Bu çalışmada, diyabetik ayak için IL-12 P70, IL-17 ve IL-18’in belirteç olarak kullanılabileceği sonucu çıkmaktadır. Kronik iltihaplı hastalıklarda IL-12 P70, IL-17 ve IL-18’in belirteç olarak rollerini göstermek için başka çalışmalara ihtiyaç vardır.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433- 42.
  • The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20 (Suppl 1):1183-97.
  • Weigelt C, Rose B, Poschen U, Ziegler D, Friese G, Kempf K, et al. Immune mediators in patients with acute diabetic foot syndrome. Diabetes Care 2009;32:1491-6.
  • Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis 2004;39:885-910.
  • Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, et al. Diabetic foot ulcers: part II. Management. J Am Acad Dermatol 2014; 70: 21.e1-24; quiz 45-6.
  • Moura LI, Dias AM, Carvalho E, de Sousa HC. Recent advances on the development of wound dressings for diabetic foot ulcer treatment: A review. Acta Biomater 2013;9:7093-114.
  • Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, et al. CD40 triggering of heterodimeric IL-12 P70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000;13:453-62.
  • Trinchieri G. Function and clinical use of interleukin-12. Curr Opin Hematol 1997;4:59-66.
  • Stern AS, Preskey DH. Interleukin 12—an integral cytokine in the immune response. Life Sci 1996;58:639-54.
  • Skarsvik S, Ludvigsson J, Vaarala O. Aberrant regulation of interleukin-12 receptor 2 chain on type 1 cytokine stimulated T lymphocytes in type 1 diabetes. Immunology 2005;114:287-93.
  • Ke Y, Liu K, Huang GQ, Cui Y, Kaplan HJ, Shao H, et al. Anti- inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009;182:3183-90.
  • Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012;181:8-18.
  • Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009;58:1302-11.
  • Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
  • Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, Mühl H, et al. Overview of interleukin 18; more than an interferon gama inducing factor. J Leukoc Biol 1998;63:658-64.
  • Oikawa Y, Shimada A, Kasuga A, Morimoto J, Osaki T, Tahara H, et al. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol 2003;171:5865-75.
  • Tuttolomondo A, Casuccio A, Guercio G, Maida C, Del Cuore A, Di Raimondo D, et al. Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome. Cardiovasc Diabetol 2017;16:2.
  • Tuttolomondo A, La Placa S, Di Raimondo D, Bellia C, Caruso A, Lo Sasso B, et al. Adiponectin, resisting and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol 2010;9:1-2.
  • Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop 2015;6:62-76.
  • Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997;25:1318-26.
  • Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984;54:718-21.
  • Herder A, Haaster B, Muller-Scholze S, Koening W, Thorand B, Holle R, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005;54:11-7.
  • Tataranni PA, Ortega EA. A burning question: Does adipokine- induced activation of the immune system mediate the effect of over nutrition on type 2 diabetes? Diabetes 2005;54:917-27.
  • Fei GZ, Huang YH, Swedenborg J, Frostegard J. Oxidised LDL modulates immune-activation by an IL-12 P70 dependent mechanism. Atherosclerosis 2003;169:77-85.
  • Brownrigg JR, Apelqvist J, Bakker K, Schaper NC, Hinchliffe RJ. Evidence-based management of PAD & the diabetic foot. Eur J Vasc Endovasc Surg 2013;45:673-81.
  • Albanesi C, Cavani A, Girolomoni G. IL-17 Is Produced by Nickel- Specific T Lymphocytes and Regulates ICAM-1 Expression and Chemokine Production in Human Keratinocytes: Synergistic or Antagonist Effects with IFN-γ and TNF-α. J Immunol 1999;162:494-502.
  • Pathare NA, Bal A, Talvalkar GV. Antani DU. Diabetic foot infections: A study of microorganisms associated with the different Wagner grades. Indian J Pathol Microbiol 1998;41:437-41.
  • Esposito K, Nappo F, Giugliano F, Di palo C, Ciotola M, Barbieri M, et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 2003;78:1135-40.
  • Fischer CP, Perstrup LB, Bernsten A, Eskildsen P, Pedersen BK. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 2005;117:152-60.
  • Frigerio S, Hollander GA, Zumsteg U. Functional IL-18 Is produced by primary pancreatic mouse islets and NIT-1 beta cells and participates in the progression towards destructive insulitis. Horm Res 2002;57:94-104.
  • Gerdes N, Sukhova GK, Libby P. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-57.
  • Sabuncu T, Eren MA, Tabur S, Dag OF, Boduroglu O. High serum concentration of interleukin-18 in diabetic patients with foot ulcers. J Am Podiatr Med Assoc 2014;104:222-6.
  • The Look AHEAD Research Group. Long Term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals with Type 2 Diabetes: Four Year Results of the Look AHEAD Trial. Arch Intern Med 2010;170:1566-75.
  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-86.
APA KALELİ S, VARIM C, nalbant a, yazar h, AKDOĞAN M (2019). Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. , 1 - 7. 10.14235/bas.galenos.2017.2077
Chicago KALELİ SÜLEYMAN,VARIM Ceyhun,nalbant ahmet,yazar hayrullah,AKDOĞAN Mehmet Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. (2019): 1 - 7. 10.14235/bas.galenos.2017.2077
MLA KALELİ SÜLEYMAN,VARIM Ceyhun,nalbant ahmet,yazar hayrullah,AKDOĞAN Mehmet Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. , 2019, ss.1 - 7. 10.14235/bas.galenos.2017.2077
AMA KALELİ S,VARIM C,nalbant a,yazar h,AKDOĞAN M Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. . 2019; 1 - 7. 10.14235/bas.galenos.2017.2077
Vancouver KALELİ S,VARIM C,nalbant a,yazar h,AKDOĞAN M Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. . 2019; 1 - 7. 10.14235/bas.galenos.2017.2077
IEEE KALELİ S,VARIM C,nalbant a,yazar h,AKDOĞAN M "Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus." , ss.1 - 7, 2019. 10.14235/bas.galenos.2017.2077
ISNAD KALELİ, SÜLEYMAN vd. "Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus". (2019), 1-7. https://doi.org/10.14235/bas.galenos.2017.2077
APA KALELİ S, VARIM C, nalbant a, yazar h, AKDOĞAN M (2019). Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. Bezmiâlem Science, 7(1), 1 - 7. 10.14235/bas.galenos.2017.2077
Chicago KALELİ SÜLEYMAN,VARIM Ceyhun,nalbant ahmet,yazar hayrullah,AKDOĞAN Mehmet Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. Bezmiâlem Science 7, no.1 (2019): 1 - 7. 10.14235/bas.galenos.2017.2077
MLA KALELİ SÜLEYMAN,VARIM Ceyhun,nalbant ahmet,yazar hayrullah,AKDOĞAN Mehmet Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. Bezmiâlem Science, vol.7, no.1, 2019, ss.1 - 7. 10.14235/bas.galenos.2017.2077
AMA KALELİ S,VARIM C,nalbant a,yazar h,AKDOĞAN M Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. Bezmiâlem Science. 2019; 7(1): 1 - 7. 10.14235/bas.galenos.2017.2077
Vancouver KALELİ S,VARIM C,nalbant a,yazar h,AKDOĞAN M Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus. Bezmiâlem Science. 2019; 7(1): 1 - 7. 10.14235/bas.galenos.2017.2077
IEEE KALELİ S,VARIM C,nalbant a,yazar h,AKDOĞAN M "Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus." Bezmiâlem Science, 7, ss.1 - 7, 2019. 10.14235/bas.galenos.2017.2077
ISNAD KALELİ, SÜLEYMAN vd. "Interleukins As a Marker of Inflammation in Diabetic Foot Syndrome and Type 2 Diabetes Mellitus". Bezmiâlem Science 7/1 (2019), 1-7. https://doi.org/10.14235/bas.galenos.2017.2077
Sayfa Oluşturulma Tarihi
23-04-2024 8:50

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları